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Maximillian Rogers, PhD; Claudia Goettsch, PhD; Elena Aikawa, MD, PhD
C ardiovascular calciﬁcation is a prominent feature ofchronic inﬂammatory disorders that associate with
signiﬁcant morbidity and mortality. Vascular calciﬁcation is
highly prevalent in patients with chronic kidney disease (CKD),
a multifactorial disorder. CKD often results from hypertension
and diabetes, and patients with CKD are among the
highest-risk groups for cardiovascular events. Notably, CKD
accelerates the development of atherosclerosis. Our group
and others have demonstrated that CKD causes excessive
vascular inﬂammation and calciﬁcation.1 CKD is characterized
by increased serum phosphate levels, which is, in turn,
associated with the progression of calciﬁcation. But phos-
phate binder therapy reportedly has no effect on vascular
calciﬁcation in CKD patients,2 suggesting that targeting
phosphate alone cannot improve vessel stiffness. A variety
of other therapies, which have produced mixed results at best,
have been tested to prevent or hinder the progression of
vascular calciﬁcation in CKD.3 A greater understanding of the
mineralization process itself may therefore lead to new and
effective therapeutics for vascular calciﬁcation in CKD.
In vitro and in vivo models of cardiovascular calciﬁcation
have helped generate a greater mechanistic understanding
of the vascular calciﬁcation process. A common model of
CKD is apolipoprotein E-deﬁcient (ApoE/) or low-density
lipoprotein receptor-deﬁcient (ldlr/) mice subjected to 5/
6 nephrectomy and fed a high-fat, high-cholesterol diet.4
Similar to dysmetabolic CKD patients, both arterial intimal
and medial calciﬁcation occurs in these animals. The use of
5/6 nephrectomy in mice with varying diets allows for the
investigation of medial calciﬁcation, which represents
patients with renal failure undergoing hemodialysis. Each
model recapitulates the formation of calciﬁcation in distinct
vascular layers, which may lead to different clinical out-
comes (Figure).
Clinically, vascular calciﬁcation occurs in the vessel intima
or media and often overlaps, particularly in a growing
population of patients with CKD-related atherosclerosis. The
process of intimal calciﬁcation associates with atherosclerotic
vascular disease, observed as spotty calciﬁcations of the
atherosclerotic plaques, where small hydroxyapatite mineral
clefs (microcalciﬁcations) seem to associate with cholesterol
crystals observed in early lesions.5 These microcalciﬁcations
in the plaque could provoke a rupture of vulnerable plaque.6
Medial calciﬁcation occurs primarily in association with CKD
and diabetes, and is independent of hypercholesterolemia.
The sheet-like calciﬁcations of the tunica media can lead to
increased vascular stiffness and reduced compliance of
vessels. The differences between medial and intimal calciﬁ-
cation stress the importance of choosing appropriate disease
models for mechanistic and therapeutic studies.
Pathogenesis of vascular calciﬁcation is complex—beyond
just a simple precipitation of calcium and phosphate, it is
instead an active, cell-regulated process. Several cell types
likely play a role in the vascular calciﬁcation process,
including smooth muscle cells (SMCs),7 circulating bone
marrow-derived cells,8 and macrophages.5 Vascular calciﬁca-
tion mechanistic studies have focused on cellular differenti-
ation, calcium and phosphate homeostasis, loss of inhibition,
apoptosis, the release of calcifying vesicles, and changes in
the extracellular matrix (ECM) among several other cellular
processes3 (Figure). Osteogenic transition of vascular SMCs
or stem cells is induced by bone morphogenetic proteins,9
high phosphate levels,10 inﬂammation,11,12 and oxidative
stress,13 and leads to a unique molecular pattern marked by
osteogenic transcription factors. Emerging evidence also
suggests that alternative mechanisms independent of oste-
ogenic differentiation, including the release of matrix vesicles
by SMCs or macrophages, may contribute to vascular
calciﬁcation in CKD.5,14 Understanding the connections
between these mechanisms and signaling pathways could
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provide novel mechanistic insight into the calciﬁcation
process, and potentially help lead to cardiovascular disease
therapeutics.
In this issue of JAHA, Masuda et al15 build on previous
studies linking tumor necrosis factor a (TNFa) to vascular
calciﬁcation, while providing a novel link between inﬂamma-
tion, endoplasmic reticulum stress, and calciﬁcation. Their
study found that administering TNFa to mouse vascular SMCs
dose-dependently induced the protein kinase RNA-like endo-
plasmic reticulum kinase (PERK)—eukaryotic initiation factor
2a (eIF2a)-activating transcription factor 4 (ATF4)—C/EBP
homologous protein (CHOP) axis of the endoplasmic reticulum
stress response.
Suggesting that inﬂammation may regulate vascular calci-
ﬁcation through an endoplasmic reticulum stress pathway, the
authors also showed short hairpin RNA-mediated knockdowns
of PERK, ATF4, and CHOP led to signiﬁcant reductions in both
TNFa-induced calcium deposition and alkaline phosphatase
activity. Supporting their in vitro ﬁndings, both phospho-ATF4
and total ATF4, along with CHOP expression levels, increased
signiﬁcantly in the aortas of 5/6 nephrectomy ApoE/ mice
on a high-fat, high-cholesterol diet. When treated with
inﬂiximab to block TNFa, or with 2 different chemical
chaperones to reduce endoplasmic reticulum stress, calciﬁed
lesions decreased signiﬁcantly in these CKD mice. The
inﬂiximab results provide further support for targeting
inﬂammation as a means of blocking vascular calciﬁcation,
which had been previously reported by another group using
ldlr/ diabetic mice.16
On a mechanistic level, treatment of these CKD mice with
the chemical chaperones also led to a signiﬁcant reduction in
the expression of a type III sodium-dependent phosphate
transporter, PiT-1, possibly mediated through a reduction of
CHOP expression. This study also demonstrated that control-
ling the expression of PiT-1 through CHOP overexpression
correlated with the amount of inorganic phosphate uptake
in SMCs. Of importance relating to this result, PiT-1 was
shown previously to participate in the vascular calciﬁcation
process.17
The ﬁndings of Masuda et al suggest that inﬂammation at
least partly regulates vascular calciﬁcation through activating
an endoplasmic reticulum stress pathway, which in turn may
increase inorganic phosphate uptake, leading to increased
mineralized calcium deposition and osteogenic differentiation.
The growing connection of endoplasmic reticulum stress
to vascular calciﬁcation is intriguing, considering that this
stress response process has also been connected to bone
formation.18
Figure. Modeling human vascular calciﬁcation in mice. Human disease associated intimal and medial vascular calciﬁcation diagramed with
plausible mechanisms and commonly used mouse models. ApoE/ indicates apolipoprotein E-deﬁcient; Ca, calcium; CKD, chronic kidney
disease; ldlr/, low-density lipoprotein receptor-deﬁcient; P, phosphate; WT, wild type.
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Besides inﬂammation, many additional mechanistic factors
have been proposed and likely play a role in vascular
calciﬁcation in combination with or independently of the
inﬂammation driven process. For example, previous studies19
have demonstrated that some components of the ECM
(elastin, collagen) could be important factors in the regulation
of calciﬁcation progression.1 Exactly how the ECM compo-
nents and the factors that regulate ECM remodeling, such as
matrix metalloproteases and cathepsins, could lead to medial
calciﬁcation is not yet fully understood. Furthermore, addi-
tional unreported factors may also be involved in this
mechanistic pathway.
A report by Purnomo et al20 in this issue of JAHA examined
the role of ECM in the development of vascular calciﬁcation,
by highlighting the role of glycosaminoglycans (GAG). The
study found that exostosin-like glycosyltransferase 2 (EXTL2)
deﬁciency caused increased heparin sulfate and chondroitin-
sulfate in the aortas of EXTL2-deﬁcienct mice. When CKD was
induced in mice by 5/6 nephrectomy along with a high-phos-
phate diet—a different CKD model than that used by Masuda
et al—elevated calciﬁcation was observed in the media layer
of the aorta, which is characterized by increased GAG levels.
The use of 5/6 nephrectomy along with a high-phosphate diet
allowed other aspects of CKD, in addition to vascular
calciﬁcation, to be modeled. EXTL2-deﬁcient CKD mice had
also higher systolic blood pressure compared to wild-type
mice, which might be due to increased vascular calciﬁcation
accompanied by increased stiffness and decreased compliance
of the arteries.
Importantly, CKD itself increased heparin sulfate and
chondroitinsulfate in wild-type mice, which might accelerate
the progression of vascular calciﬁcation. In line with this
evidence, treatment with heparitinase and chondroitinase
prevented calciﬁcation in aorta explants. As such, changes in
the sulfation pattern of GAG could conceivably contribute to
the vascular calciﬁcation process. Further study is required,
however, to dissect the full inﬂuence of speciﬁc GAG sulfation
patterns in triggering pathways involved in the development of
vascular calciﬁcation.
In the EXTL2-deﬁcient mice, Runx2 and collagen 1A1 were
increased, whereas SMC markers were decreased. Purnomo
et al suggested that under high-phosphate conditions heparin
sulfate and chondroitinsulfate trigger a signaling pathway that
further induces SMC osteogenic transition. Whether similar
results occur in EXTL2-deﬁcient mice under other disease-rel-
evant conditions remains to be determined. For example,
testing this pathway in dyslipidemic conditions, such as those
used by Masuda et al, may help reveal additional information
about the disease process (eg, whether ECM-based calciﬁca-
tion effects intimal calciﬁcation).
Taken together, the results of this study provide novel
insights into the role of GAG in calciﬁcation, and further
suggest that modulation of the ECM might be a therapeutic
target in the prevention of vascular calciﬁcation in CKD.
While these two studies depicting the role of two
potentially independent mechanisms of calciﬁcation in CKD
help to connect previous ﬁndings from other groups, several
questions remain unanswered—notably, how inﬂammatory
cytokines like TNFa activate endoplasmic reticulum stress,
and whether GAG are increased in the aortas of CKD patients.
Just how these proposed mechanisms will ultimately translate
to the human disease condition remains to be seen. While
mouse models are useful, an important next step to furthering
these results will be to test these working hypotheses in
human cells and tissues.
In summary, the work of Masuda et al and Purnomo et al
adds to several existing working hypotheses on how vascular
calciﬁcation occurs, particularly in CKD. Of paramount
importance in interpreting the results of these and other
studies involves understanding the model used and the type
of calciﬁcation it reﬂects. Differences between intimal and
medial calciﬁcation may also be reﬂected in the mechanisms
behind their development. Each animal and cell culture model
has limits; no one model fully encapsulates the human
disease process. Each new study, however, incrementally
adds toward our growing understanding of the process of
vascular calciﬁcation.
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